Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRSN
Previous Symbol
CUSIPN/A
Phone617-498-0020
Debt
Debt-to-Equity RatioN/A
Current Ratio2.86
Quick Ratio2.86
Price-To-Earnings
Trailing P/E Ratio-1.48
Forward P/E Ratio-1.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.55 million
Price / Sales6.31
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.08 per share
Price / Book1.55
Profitability
EPS (Most Recent Fiscal Year)($3.22)
Net Income$-38,700,000.00
Net Margins-440.47%
Return on Equity-110.44%
Return on Assets-49.85%
Miscellaneous
Employees78
Outstanding Shares23,180,000
Market Cap$115.91 million
OptionableNot Optionable
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc (NASDAQ:MRSN) posted its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.16. The firm had revenue of $2.15 million for the quarter, compared to the consensus estimate of $3.98 million. Mersana Therapeutics had a negative return on equity of 110.44% and a negative net margin of 440.47%. View Mersana Therapeutics' Earnings History.
When is Mersana Therapeutics' next earnings date?
What price target have analysts set for MRSN?
6 analysts have issued twelve-month target prices for Mersana Therapeutics' stock. Their forecasts range from $16.00 to $61.00. On average, they expect Mersana Therapeutics' share price to reach $28.60 in the next twelve months. This suggests a possible upside of 498.3% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.
What is the consensus analysts' recommendation for Mersana Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.
Has Mersana Therapeutics been receiving favorable news coverage?
Headlines about MRSN stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mersana Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Are investors shorting Mersana Therapeutics?
Mersana Therapeutics saw a drop in short interest during the month of November. As of November 30th, there was short interest totalling 1,536,990 shares, a drop of 27.2% from the November 15th total of 2,111,689 shares. Based on an average daily trading volume, of 144,981 shares, the short-interest ratio is currently 10.6 days. Currently, 16.0% of the shares of the stock are short sold. View Mersana Therapeutics' Current Options Chain.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include Rigel Pharmaceuticals (RIGL), Corium International (CORI), Beyondspring (BYSI), BioSpecifics Technologies (BSTC), GlycoMimetics (GLYC), Dermira (DERM), Cytokinetics (CYTK), Tyme Technologies (TYME), Achillion Pharmaceuticals (ACHN), Xeris Pharmaceuticals (XERS), Dova Pharmaceuticals (DOVA), Kindred Biosciences (KIN), TG Therapeutics (TGTX), ZIOPHARM Oncology (ZIOP) and Odonate Therapeutics (ODT).
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Ms. Anna Protopapas, Pres, CEO & Director (Age 54)
- Mr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 54)
- Dr. Donald A. Bergstrom, Former Sr. VP & Chief Medical Officer (Age 46)
- Mr. Mikhail Papisov Ph.D., Co-Founder
- Mr. Wayne Foster, VP of Fin.
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Mersana Therapeutics' major shareholders?
Mersana Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.43%), Vanguard Group Inc (2.59%), Vanguard Group Inc. (2.59%), EcoR1 Capital LLC (2.14%), JPMorgan Chase & Co. (1.38%) and JPMorgan Chase & Co. (1.38%). Company insiders that own Mersana Therapeutics stock include M James Barrett and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.
Which institutional investors are selling Mersana Therapeutics stock?
Which institutional investors are buying Mersana Therapeutics stock?
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $4.78.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $115.91 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.
What is Mersana Therapeutics' official website?
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
